Luzhu Biotech - Public Comps and Valuation Multiples

Luzhu Biotech Overview

About Luzhu Biotech

Beijing Luzhu Biotechnology Co Ltd is a biotechnology company committed to developing human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. The Group’s product pipeline consisted of three clinical-stage product candidates, including its Core Product, LZ901, and six pre-clinical-stage product candidates.

Founded

2013

HQ

Employees

164

Website

luzhubiotech.com

Sectors

Vaccines & Immunotherapies
Biopharmaceuticals
BioTech

Financials

Last FY Revenue n/a

Last FY EBITDA -$18.3M

EV

$571M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Luzhu Biotech Financials

See Luzhu Biotech valuation multiples based on analyst estimates

Luzhu Biotech P&L

In the most recent fiscal year, Luzhu Biotech reported EBITDA of -$18.3M.

Luzhu Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Luzhu Biotech valuation multiples based on analyst estimates

	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	XXX	n/a	XXX	XXX	XXX
Gross Profit	XXX	n/a	XXX	XXX	XXX
Gross Margin	XXX	n/a	XXX	XXX	XXX
EBITDA	XXX	-$18.3M	XXX	XXX	XXX
EBITDA Margin	XXX	n/a	XXX	XXX	XXX
EBIT	XXX	-$23.5M	XXX	XXX	XXX
EBIT Margin	XXX	n/a	XXX	XXX	XXX
Net Profit	XXX	-$21.6M	XXX	XXX	XXX
Net Margin	XXX	n/a	XXX	XXX	XXX
Net Debt	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Luzhu Biotech including revenue, profitability, and margin analysis across different time periods.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	-$18.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	-$23.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	-$21.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Luzhu Biotech

This financial data table provides comprehensive performance metrics for Luzhu Biotech, a company based in Hong Kong. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

Fiscal year EBITDA was -$18.3M.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Luzhu Biotech. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Luzhu Biotech Stock Performance

Luzhu Biotech has current market cap of HKD 4.7B (or $603M), and EV of HKD 4.4B (or $571M).

Market Cap Evolution

Luzhu Biotech Stock Data

As of January 16, 2026, Luzhu Biotech's stock price is HKD 24 (or $3).

See Luzhu Biotech trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$571M	$603M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Luzhu Biotech Valuation Multiples

Luzhu Biotech's trades at n/a EV/Revenue multiple, and -31.2x EV/EBITDA.

See valuation multiples for Luzhu Biotech and 15K+ public comps

Luzhu Biotech Financial Valuation Multiples

As of January 16, 2026, Luzhu Biotech has market cap of $603M and EV of $571M.

Equity research analysts estimate Luzhu Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Luzhu Biotech's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$603M	XXX	$603M	XXX	XXX	XXX
EV (current)	$571M	XXX	$571M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	n/a	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	-31.2x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	-24.3x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	-27.9x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-24.1x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Luzhu Biotech Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Luzhu Biotech Margins & Growth Rates

Luzhu Biotech's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.1M for the same period.

Luzhu Biotech's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Luzhu Biotech's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Luzhu Biotech and other 15K+ public comps

Luzhu Biotech Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	n/a	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial